A comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: A multicenter study.
Takeshi HatanakaSatoru KakizakiAtsushi HiraokaToshifumi TadaMasashi HirookaKazuya KariyamaJoji TaniMasanori AtsukawaKoichi TakaguchiEi ItobayashiShinya FukunishiKunihiko TsujiToru IshikawaKazuto TajiriHironori OchiSatoshi YasudaHidenori ToyodaChikara OgawaKeisuke YokohamaHiroki NishikawaTakashi NishimuraNoritomo ShimadaKazuhito KawataHisashi KosakaAtsushi NaganumaYutaka YataHideko OhamaHidekatsu KurodaTomoko AokiKazunari TanakaTakaaki TanakaFujimasa TadaKazuhiro NousoAkihiro MorishitaAkemi TsutsuiTakuya NaganoNorio ItokawaTomomi OkuboTaeang AraiMichitaka ImaiYohei KoizumiShinichiro NakamuraMasaki KaiboriHiroko IijimaYoichi HiasaMasatoshi KudoTakashi Kumadanull nullPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2023)
Atez/Bev showed comparable effectiveness to LEN in HCC patients aged 80 years and older. Given the results of post-progression treatment and discontinuation due to adverse events, Atez/Bev could serve as a first-line treatment even for elderly HCC patients. This article is protected by copyright. All rights reserved.